Published in

American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 12(64), 2020

DOI: 10.1128/aac.01013-20

Links

Tools

Export citation

Search in Google Scholar

Piperaquine exposure is altered by pregnancy, HIV and nutritional status in Ugandan women

Journal article published in 2020 by Emma Hughes, Marjorie Imperial, Erika Wallender ORCID, Richard Kajubi, Liusheng Huang, Prasanna Jagannathan ORCID, Nan Zhang, Mary Muhindo, Norah Mwebaza, Abel Kakuru ORCID, Tamara D. Clark, Paul Natureeba, Bishop Opira, Miriam Nakalembe, Moses W. Mwima and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Orange circle
Published version: archiving restricted
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Dihydroartemisinin-piperaquine (DHA-PQ) provides highly effective therapy and chemoprevention for malaria in pregnant African women. PQ concentrations of >10.3 ng/ml have been associated with reduced maternal parasitemia, placental malaria, and improved birth outcomes. We characterized the population pharmacokinetics (PK) of PQ in a post hoc analysis of human immunodeficiency virus (HIV)-infected and -uninfected pregnant women receiving DHA-PQ as chemoprevention every 4 or 8 weeks.